Dexmedetomidine + Placebo

Phase 3Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Delirium

Conditions

Delirium

Trial Timeline

Apr 1, 2007 → Sep 1, 2007

NCT ID

NCT00464763

About Dexmedetomidine + Placebo

Dexmedetomidine + Placebo is a phase 3 stage product being developed by Pfizer for Delirium. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00464763. Target conditions include Delirium.

What happened to similar drugs?

5 of 12 similar drugs in Delirium were approved

Approved (5) Terminated (2) Active (6)

✅Rivastigmine + PlaceboNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ParecoxibPfizerApproved

✅Cyclopofol + PropofolHaisco Pharmaceutical GroupApproved

✅Dexmedetomidine Hydrochloride GroupBrain BiotechApproved

🔄Suvorexant + PlaceboMerckPhase 3

🔄Rivastigmine prevention of deliriumNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02004613	Approved	Completed	Jun 1, 2013	Dec 18, 2020	Heart Disease
NCT00464763	Phase 3	Withdrawn	Apr 1, 2007	Sep 1, 2007	Delirium
NCT00460473	Phase 3	Terminated	Apr 1, 2007	Nov 1, 2007	Delirium
NCT00398827	Phase 3	Completed	Dec 1, 2006	May 1, 2007	Anesthesia

Competing Products

17 competing products in Delirium

See all competitors

Product	Company	Stage	Hype Score
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	42
Suvorexant + Placebo	Merck	Phase 3	40
Suvorexant 20 mg + Placebo	Merck	Phase 2	35
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Rivastigmine Patch	Novartis	Approved	43
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	40
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17